RRM2 and cancer: Namely, FOXM1 promotes epithelial-mesenchymal transition and metastasis formation for breast and various other cancers [63–65], RRM2 contributes to poor survival and tamoxifen resistance development [66, 67], while expression levels of CDK1, PLK1 and RACGAP1 were shown to be prognostic markers [68–70].